| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | paclitaxel | FIMM | pan-cancer | AAC | -0.44 | 0.0003 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.17 | 0.0003 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.16 | 0.0005 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.19 | 0.001 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.13 | 0.003 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | 0.095 | 0.004 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | 0.21 | 0.005 |
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.007 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.01 |